A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes

Pharmacology Research and Perspectives

Volumn 4, Issue 6, 2016, Pages

  Chen, Yanyun ^a   Song, Min ^a   Riley, Jonathan P ^a   Hu, Charlie C ^a   Peng, Xianbu ^a   Scheuner, Donalyn ^a   Bokvist, Krister ^a   Maiti, Pranab ^b   Kahl, Steven D ^a   Montrose Rafizadeh, Chahrzad ^a   Hamdouchi, Chafiq ^a   Miller, Anne Reifel ^a  

^a ELI LILLY AND COMPANY   (United States)

^b JUBILANT BIOSYS LTD   (India)

Author keywords

FFAR1; GPCR; GPR40; hyperglycemia; insulin; type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; BETA ARRESTIN; G PROTEIN COUPLED RECEPTOR 40; LY2881835; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CALCIUM TRANSPORT; CHEMICAL STRUCTURE; CHEMOLUMINESCENCE; GLUCOSE TOLERANCE TEST; HUMAN; HUMAN CELL; INSULIN RELEASE; INSULIN RESISTANCE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING;

EID: 85026612809     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.278     Document Type: Article

References (23)

1. Alquier T, Peyot ML, Latour MG, Kebede M, Sorensen CM, et al. (2009). Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 58: 2607–2615.
2. Araki T, Hirayama M, Hiroi S, Kaku K (2012). GPR40-induced insulin secretion by the novel agonist TAK-875: first clinical findings in patients with type 2 diabetes. Diabetes Obes Metab 14: 271–278.
3. Briscoe C, Tadayyon M, Andrews J, Benson W, Chambers J, Eilert M, et al. (2003). The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 278: 11303–11311.
4. Briscoe C, Peat A, McKeown S, Corbett D, Goetz A, Littleton T, et al. (2006). Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol 148: 619–628.
5. Brown A, Jupe S, Briscoe C (2005). A family of fatty acid binding receptors. DNA Cell Biol 24: 54–61.
6. Brown S, Dransfield P, Vimolratana M, Jiao X, Zhu L, Pattaropong V, et al. (2012). Discovery of AM-1638: a potent and orally bioavailable GPR40/FFA1 full agonist ACS Med. Chem Lett 3: 726–730.
7. Burant C, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, Xie B, et al. (2012). TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomized, double-blind, placebo controlled trial. Lancet 379: 1403–1411.
8. Christiansen E, Urban C, Merten N, Liebscher K, Karlsen KK, Hamacher A, et al. (2008). Discovery of potent and selective agonists for the free fatty acid receptor 1 (FFA(1)/GPR40), a potential target for the treatment of type II diabetes. J Med Chem 51: 7061–7064.
9. Edfalk S, Steneberg P, Edlund H (2008). Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57: 2280–2287.
10. Feng D, Luo Z, Roh S, Hernandez M, Tawadros N, et al. (2006). Reduction in voltage-gated K+ currents in primary cultured rat pancreatic beta-cells by linoleic acids. Endocrinology 147: 674–682.
11. 2+ channel and link to insulin release. Am J Physiol Endocrinol Metab 289: E670–E677.
12. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, et al. (2003). Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422: 173–176.
13. Lin D, Zhang J, Zhuang R, Li F, Nguyen K, Chen M, et al. (2011). AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS ONE 6: e27270.
14. Nakamoto K, Nishinaka T, Matsumoto K, Kasuya F, Mankura M, Koyama Y, et al. (2012). Involvement of the long-chain fatty acid receptor GPR40 as a novel pain regulatory system. Brain Res 1432: 74–83.
15. Ogawa T, Hirose H, Miyashita K, Saito I, Saruta T (2005). GPR40 gene Arg211His polymorphism may contribute to the variation of insulin secretory capacity in Japanese men. Metab, Clin Exp 54: 296–299.
16. Prentki M, Tornheim K, Corkey B (1997). Signal transduction mechanisms in nutrient-induced insulin secretion. Diabetologia 40: S32–S41.
17. Tan C, Feng Y, Zhou Y, Eiermann G, Petrov A, Zhou C, et al. (2008). Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 57: 2211–2219.
18. Tanaka H, Yoshida S, Oshima H, Minoura H, Negoro K, Yamazaki T, et al. (2013). Chronic treatment with Novel GPR40 agonists improve whole-body glucose metabolism based on the glucose-dependent insulin secretion. J Pharmacol Exp Ther 346: 443–452.
19. Tomita T, Masuzaki H, Iwakura H, Fujikura J, Noguchi M, Tanaka T, et al. (2006). Expression of the gene for a membrane-bound fatty acid receptor in the pancreas and islet cell tumours in humans: evidence for GPR40 expression in pancreatic beta cells and implications for insulin secretion. Diabetologia 49: 962–968.
20. Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, Yasuma T, et al. (2011). TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther 339: 228–237.
21. Vettor R, Granzotto M, De Stefani D, Trevellin E, Rossato M, et al. (2008). Loss-of-function mutation of the GPR40 gene associates with abnormal stimulated insulin secretion by acting on intracellular calcium mobilization. J Clin Endocrinol Metab 93: 3541–3550.
22. World Health Organization. 2016. Global Report on Diabetes ISBN 978 92 4 156525 7
23. Zawalich W, Zawalich K (1996). Regulation of insulin secretion by phospholipase C. Am J Physiol Endocrinol Metab 271: E409–E416.